Article

beta-arrestins: traffic cops of cell signaling.

Howard Hughes Medical Institute, Duke University Medical Center, DUMC Box 3821, Durham, NC 27710, USA.
Current Opinion in Cell Biology (Impact Factor: 8.74). 05/2004; 16(2):162-8. DOI: 10.1016/j.ceb.2004.01.001
Source: PubMed

ABSTRACT Once thought to function only in the desensitization of seven membrane spanning receptors (7MSRs), the ubiquitous beta-arrestin molecules are increasingly appreciated to play important roles in the endocytosis and signaling of these receptors. These functions reflect the ability of the beta-arrestins to bind an ever-growing list of signaling and endocytic elements, often in an agonist-dependent fashion. One heavily studied system is that leading to MAP kinase activation via beta-arrestin-mediated scaffolding of these pathways in a receptor-dependent fashion. The beta-arrestins are also found to be involved in the regulation of novel receptor systems, such as Frizzled and TGFbeta receptors.

0 Followers
 · 
183 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Raf kinases have been intensely studied since their discovery 30 years ago. The Ras-Raf-MEK-ERK/MAPK (extra cellular signal-regulated kinase/mitogen-activated protein kinase) signaling pathway is at the heart of the signaling networks that control many fundamental cellular processes and Raf kinases takes centre stage in MAPK pathway which is now appreciated to be one of the most common sources of the oncogenic mutations in cancer. The dependency of tumors on this pathway has been clearly demonstrated by targeting its key nodes; however, blockade of the central components of MAPK pathway may have some unexpected side effects. Over the past few years, the Raf-interactome or Raf-interacting proteins have emerged as promising targets for protein-directed cancer therapy. This review focuses on the diversity of Raf-interacting proteins and discusses the mechanisms by which these proteins regulate Raf function as well as implications of targeting Raf-interacting proteins in the treatment of human cancer.This article is protected by copyright. All rights reserved.
    FEBS Journal 10/2014; 282(1). DOI:10.1111/febs.13113 · 3.99 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: IGF-1R potential as a therapeutic target in cancer has not been fulfilled, as clinical trial results are disappointing.•The IGF-1R model used for drug development might have been too simplistic.•This review emphasise the updating of the IGF-1R’s classification from an RTK, to an RTK/GPCR functional hybrid, which integrates both canonical kinase signalling with many functions characteristic of a GPCR.•This review advocates recognition of IGF-1R as therapeutic target for cancer and is indicating IGF-1R biased agonists as an alternative strategy to control IGF-1R activities.
    Growth Hormone & IGF Research 10/2014; 25(1). DOI:10.1016/j.ghir.2014.10.002 · 1.33 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The self-renewal ability of the leukemia initiating cell-enriched subpopulation is critical for leukemia initiation and maintenance. However, the regulation of leukemia initiating cells for the leukemia progression is poorly understood. In this study, we observed that β-Arrestin1, a multiple-function protein, is elevated in leukemia initiating cells-enriched fraction from B-lineage acute lymphoblastic leukemia patients. The loss of β-Arrestin1 in leukemia initiating cells-enriched fraction attenuates its self-renewal capacity both in vitro and in vivo. Further experiments showed that the mRNA expression level of β-Arrestin1 is negatively correlated with that of PTEN in leukemia initiating cells-enriched fraction. Moreover, DNA methylation of the PTEN promoter region, the activity and expression of DNMTs were enhanced in the leukemia initiating cells-enriched fraction. The inhibition of DNMT1 activity impaired the self-renewal and increased expression of PTEN of leukemia initiating cells-enriched fraction. In addition, depletion of β-Arrestin1 significantly decreased DNMT1 activity and PTEN methylation, and consistently increased PTEN expression in leukemia initiating cells-enriched fraction. Our study reveals a novel function of β-Arrestin1 in the regulation of the self-renewal of leukemia initiating cells-enriched fraction from B-lineage acute lymphoblastic leukemia patients related to DNMT1 activity, indicating that β-Arrestin1 is a potential therapeutic target in B-lineage acute lymphoblastic leukemia. Copyright © 2014. Published by Elsevier Ireland Ltd.
    Cancer Letters 11/2014; 357(1). DOI:10.1016/j.canlet.2014.11.025 · 5.02 Impact Factor

Full-text (2 Sources)

Download
140 Downloads
Available from
May 28, 2014